The United Arab Emirates is a key strategic market for innovative AI-powered medical devices. However, many international manufacturers make a costly assumption: that their FDA clearance or European CE mark will grant them immediate access. The reality is that the UAE's regulatory framework, while recognizing these approvals, has its own distinct and mandatory registration process that can lead to significant delays and unforeseen costs if not navigated correctly. Imagine launching your groundbreaking, FDA-cleared diagnostic software in Dubai, only to be halted for months. You're suddenly faced with unexpected demands for a local authorized representative, a complete reformatting of your technical dossier, and even requests for new clinical data to validate your algorithm on the local population. This is a common and costly setback that can derail an entire market entry strategy. Key questions answered in this episode: - Why is a CE Mark or FDA approval just the first step for UAE market entry? - What is the critical "reference country" rule and how does it impact your submission timeline? - Does the UAE's MOHAP require local clinical data for AI algorithms trained on other populations? - What are the specific cybersecurity and data privacy standards your SaMD must meet in the UAE? - How can appointing the right UAE Authorized Representative make or break your launch? - What are the hidden costs in reformating your US or EU technical file for a MOHAP submission? - What is a Certificate of Free Sale and why is it non-negotiable for UAE registration? At Pure Global, we specialize in turning these complex regulatory hurdles into a clear path to market. We offer end-to-end solutions, from acting as your local UAE representative to leveraging AI-driven tools to adapt your technical dossier for a seamless submission. Don't let regulatory surprises derail your MENA expansion. Contact us today at [email protected] or visit https://pureglobal.com/ to secure your market access.